CJC-1295 / Ipamorelin

CJC-1295 and Ipamorelin are two complementary peptides that work through distinct receptor pathways to support the body's natural growth hormone release. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that binds to GHRH receptors on the pituitary gland, while Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release through a separate pathway without significantly affecting cortisol or appetite hormones. Used together, these peptides are designed to produce a synergistic, pulsatile increase in the body's own growth hormone secretion, mimicking the body's natural release patterns rather than introducing exogenous GH directly. EdgeRx offers this combination as a foundational clinician-supervised peptide protocol, prescribed by licensed physicians for eligible patients pursuing recovery, body composition, or performance-related goals.